Expression of SEMA3F and ATF4 in Laryngeal Carcinoma and Prediction of Postoperative Recurrence and Metastasis

Abstract

Abstract: Objective Exploration (SEMA3F), transcriptional activator 4 (ATF 4) expression in laryngeal cancer tissue and predictive value of postoperative recurrence and metastasis. Methods A total of 60 patients who were treated for laryngeal cancer in the Affiliated Hospital of Putian University from August 2016 to August 2022, 37 patients with pathologically confirmed postoperative recurrence and metastasis were divided into recurrence and metastasis group, and the other 23 patients without postoperative recurrence and metastasis were divided into no recurrence and metastasis group. The positive rates of SEMA3F and ATF 4 were determined by immunohistochemistry and SEMA3F and ATF 4 by RT-PCR. The predictive value of SEMA3F and ATF 4 for postoperative recurrence and metastasis in patients with laryngeal cancer was analyzed. Results Compared with the non-recurrent metastasis group, SEMA3F expression and ATF 4 expression decreased in laryngeal carcinoma tissue; SEMA3F mRNA expression decreased and ATF4 mRNA expression increased (P<0.05). Compared with the unmetastatic group, the expression levels of carcinoembryonic antigen (CEA), sugar antigen 199 (CA199), and sugar antigen 125 (CA125) were decreased in the metastatic group (P<0.05). Logistic Regression analysis showed that CEA, CA199, CA125, SEMA3F, and ATF 4 were independent risk factors for postoperative recurrence and metastasis in patients with laryngeal cancer. The ROC curve showed that the diagnostic efficacy of the combination test to predict recurrence and metastasis after laryngeal cancer was significantly higher than the single test of SEMA3F and ATF 4. Conclusion SEMA3F, ATF 4 is a risk predictor of postoperative recurrence and metastasis in laryngeal cancer patients, and it has a higher application value in the diagnosis of recurrence and metastasis after laryngeal cancer surgery.

Key words: Semaphorin 3F, Transcriptional activator 4, Laryngeal cancer, Recrudescence

摘要： 目的探究神经轴突导向因子（SEMA3F）、转录激活因子4（ATF4）在喉癌组织中表达及对患者术后复发转移的预测价值。方法选取2016年8月~2022年8月于莆田学院附属医院进行喉癌手术治疗的患者60例,将经病理学证实出现术后复发转移的37例患者分为复发转移组,其余未出现术后复发转移的23例患者分为未复发转移组。免疫组化法测定SEMA3F、ATF4蛋白阳性率;RT-PCR法检测SEMA3F、ATF4表达水平。分析SEMA3F、ATF4对喉癌患者术后复发转移的预测价值。结果与非复发转移组对比,复发转移组患者喉癌组织中的SEMA3F蛋白阳性表达降低、ATF4蛋白阳性表达升高;SEMA3F mRNA相对表达量降低,ATF4 mRNA相对表达量升高（P<0.05）。与未复发转移组相比,复发转移组癌胚抗原（CEA）、糖类抗原199（CA199）、糖类抗原125（CA125）表达水平降低（P<0.05）。Logistic回归分析显示,CEA、CA199、CA125、SEMA3F、ATF4是喉癌患者术后复发转移的独立危险因素。ROC曲线显示,联合检测预测喉癌术后复发转移的诊断效能显著高于SEMA3F、ATF4单一检测。结论 SEMA3F、ATF4是喉癌患者术后复发转移的风险预测因子,对喉癌术后复发转移具有较高的预测价值。

关键词: 神经轴突导向因子, 转录激活因子4, 喉癌, 复发

CLC Number:

R739.65

HUANG Jin-qiao, CHEN Xiu-fen, DAI Hui-ting, PAN Zhi-yong, HU Wei-qun. Expression of SEMA3F and ATF4 in Laryngeal Carcinoma and Prediction of Postoperative Recurrence and Metastasis[J]. Journal of Chengde Medical University, 2024, 41(5): 382-386.

黄金樵, 陈秀芬, 戴惠婷, 潘志勇, 胡伟群. SEMA3F、ATF4在喉癌组织中的表达及对术后复发转移的预测[J]. 承德医学院学报, 2024, 41(5): 382-386.

Add to citation manager EndNote|Ris|BibTeX

URL: http://tougao.cdmc.edu.cn:8088/EN/

http://tougao.cdmc.edu.cn:8088/EN/Y2024/V41/I5/382

References

[1] Arboleda LPA, Neves AB, Kohler HF, et al.Overview of glottic laryngeal cancer treatment recommendation changes in the NCCN guidelines from 2011 to 2022[J]. Cancer Rep (Hoboken), 2023, 6(8): e1837.
[2] Rodrigo JP, López-Álvarez F, Medina JE, et al. Treatment of the neck in residual/recurrent disease after chemoradiotherapy for advanced primary laryngeal cancer[J]. Eur J Surg Oncol, 2024, 50(7): 108389.
[3] Campbell G, Glazer TA, Kimple RJ, et al.Advances in Organ Preservation for Laryngeal Cancer[J]. Curr Treat Options Oncol, 2022, 23(4): 594-608.
[4] Mendenhall WM, Morris CG, Amdur RJ, et al.Curative-intent radiotherapy for glottic carcinoma in situ[J]. Head Neck, 2020, 42(12): 3515-3517.
[5] Hou Y, Yang X, Miao S, et al.Interactive regulation of laryngeal cancer and neuroscience[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(1): 188580.
[6] Wang C, Song D, Huang Q, et al.Advances in SEMA3F regulation of clinically high-incidence cancers[J]. Cancer Biomark, 2023, 38(2): 131-142.
[7] He F, Zhang P, Liu J, et al.ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis[J]. J Hepatol, 2023, 79(2): 362-377.
[8] 中华耳鼻咽喉头颈外科杂志编辑委员会头颈外科组,中华医学会耳鼻咽喉头颈外科学分会头颈学组,李晓明. 喉癌外科手术及综合治疗专家共识[J]. 中华耳鼻咽喉头颈外科杂志,2014,49(8):620-626.
[9] Knipper K, Lyu SI, Jung JO, et al.Semaphorin 3F (SEMA3F) influences patient survival in esophageal adenocarcinoma[J]. Sci Rep, 2024, 14(1): 20589.
[10] Kotan LD, Ternier G, Cakir AD, et al.Loss-of-function variants in SEMA3F and PLXNA3 encoding semaphorin-3F and its receptor plexin-A3 respectively cause idiopathic hypogonadotropic hypogonadism[J]. Genet Med, 2021, 23(6): 1008-1016.
[11] 郝芳,单春光,贾巧静,等. 喉癌组织中SEMA3F与NRP2的表达及临床价值[J]. 西部医学,2022,34(11):1641-1645.
[12] 王勇,宋林繁,杨光,等. 直肠癌患者肿瘤抑制因子SEMA3F、CYLD与miR-454表达水平及其相关性[J]. 中国现代普通外科进展,2018,21(2):106-109.
[13] 朱小娟,时振国,阮豪杰,等. ATF4在Siewert Ⅱ型食管胃结合部腺癌中的表达及与长期随访结果的关系[J]. 广东医学,2023,44(1):69-73.
[14] Hao L, Zhong W, Dong H, et al.ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis[J]. Gut, 2021, 70(10): 1933-1945.
[15] 刘婉,晋颖,冯晓洁,等. 茯苓酸对结肠癌细胞增殖凋亡、迁移侵袭及PERK/ATF4信号通路蛋白表达的影响[J]. 山东医药,2023,63(6):38-42.
[16] 要兆旭,彭丽娜,马海斌. 喉癌组织中ATF4、RPL41表达变化及意义[J]. 山东医药,2021,61(31):68-70.
[17] 杨雪,冯志星,彭丽娜,等. 喉癌组织中转录活性因子4和血管内皮生长因子的表达变化及其意义[J]. 山东医药,2021,61(27):27-31.